-
Human CD34+ Progenitor Cells from Mobilized Peripheral Blood (1 Million Cells)Catalog #: 3Y-101CFresh human CD34+ cells, ≥ 1 million cells, isolated from mobilized peripheral blood using positive immunomagnetic selectionSales unit: each
-
Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 10 Million
Catalog #: 2Y-101ECryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing 10 million cells
Sales unit: Ampule -
Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 25 MillionCatalog #: 2Y-101F
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 25 million cells
Sales unit: Ampule -
Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 1 MillionCatalog #: 2Y-101C
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 1 million cells
Sales unit: Ampule -
Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 5 MillionCatalog #: 2Y-101D
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 5 million cells
Sales unit: Ampule -
PASMC - Human Pulmonary Artery Smooth Muscle CellsCatalog #: CC-2581
Cryopreserved ampule of Pulmonary Artery Smooth Muscle Cells (PASMC) containing ≥ 500,000 cells
Sales unit: each -
Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 25 Million CellsCatalog #: 4Y-101FCryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 25 million cellsSales unit: each
-
Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 1 MillionCatalog #: 4Y-101CCryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 1 million cellsSales unit: each
-
Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 5 Million CellsCatalog #: 4Y-101DCryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 5 million cellsSales unit: each
-
Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 10 Million CellsCatalog #: 4Y-101ECryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 10 million cellsSales unit: each
-
Natural Killer Cells InfographicNatural Killer cells have an innate ability to recognize and destroy non-self cells.
-
3D Natural Killer Cell-mediated Cytotoxicity AssayLonza White Paper
-
3D Natural Killer (NK) Cell-mediated Cytotoxicity (CMC) Assay
-
Natural Killer (NK) Cell Expansion, Activation and Cytotoxicity AssayProtocol instructions
-
Therapeutic Approaches to Enhance Natural Killer Cell Cytotoxicity: The Force AwakensPoster published by Nature Reviews Drug Discovery, sponsored by Lonza. Natural killer (NK) cells are emerging as attractive candidates for new immunotherapeutic approaches. The poster shows the approaches to NK cell tumor targeting.
-
Transfection Protocol for Human NK Cells - Nucleofector™ I/II/2b Device SeriesInstructions of use for transfection of human natural killer cells with Nucleofector™ 1/2 Devices (incl. 1, 2b, 2N, 2S)
-
An Innovative, Highly Efficient Method for Transfecting Large Quantities of Primary Human T-cellsA strong need exists for improved cancer treatment options. Lonza's approach relies on genetically modified, patient-derived cells like T-cells or natural killer cells which express chimeric antigen receptors (CAR) targeting cancer cells.
-
NK Cell Assay using 3D Bioprinted Tumor ModelsThis white paper describes an ex vivo assay for NK cell killing activity in a 3D bioprinted cervical cancer tumor model.
-
TechSheet - Poietics™ Human Immune System CellsTechnical Product Information Sheet
-
CAR T cells in Cancer TherapyA poster developed by Nature Reviews in conjunction with Lonza to present CAR T cells in cancer therapy. This poster demonstrates the recognition of tumor peptides by T cells, CAR T cell manufacturing, the types of chimeric antigen receptors and a timeline of CAR development over more than 30 years.